Beaumont Hospital in Royal Oak announced it is enrolling patients in a study to test the AZD1222 COVID-19 vaccine. The vaccine trial is in phase 3 testing for safety and effectiveness.
Related: Pfizer says its COVID-19 vaccine candidate is 90% effective
“Because there is currently no FDA-approved vaccine to prevent COVID-19, we’re eager to have Beaumont participate as one of the trial sites. Beaumont Health cared for the most COVID-19 patients in Michigan during the surge in March and April,” Dr. Christopher Carpenter, principal investigator for the study site and chair of the Department of Medicine, said in a release. “We’re hopeful the study will attract a diverse group of participants.”
The trial is seeking about 40,000 patients nationwide. Those who meet the criteria will get two injections four weeks apart. They will not know if they got the vaccine or placebo. Two-thirds will get the vaccine and the other one-third will get a placebo.
The trial is part of Operation Warp Speed.
To apply, you must beet the criteria below.
- People 18 years of age or older, in good or stable health. They may have an underlying medical condition and still take part, if their disease is stable.
- Individuals with an increased risk of getting COVID-19 or those at greater risk of developing complications from COVID-19.
- Those who do not have a previously confirmed diagnosis of COVID-19.